Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Alberto Mussetti

Showing results (41-50 of 100) with videos related to

Pageof 10
Sort By:
JMIR Formative Research|February 18, 2021
Use of Telehealth for Domiciliary Follow-up After Hematopoietic Cell Transplantation During the COVID-19 Pandemic: Prospective Pilot StudyAlberto Mussetti, Maria Queralt Salas, Maria Condom, et al.
Supportive Care in Cancer : Official Journal of the Multinational Association of Supportive Care in Cancer|June 11, 2026
Assessing the impact of nutritional status at allogeneic stem cell transplantation on clinical outcomesAnnalisa Paviglianiti, Marta Bellver Sanchis, Marta Peña, et al.
Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation|April 10, 2017
Allogeneic Stem Cell Transplantation for Relapsed/Refractory B Cell Lymphomas: Results of a Multicenter Phase II Prospective Trial including Rituximab in the Reduced-Intensity Conditioning RegimenAnna Dodero, Francesca Patriarca, Giuseppe Milone, et al.
Kidney Medicine|August 17, 2021
Acute Kidney Injury Following Chimeric Antigen Receptor T-Cell Therapy for B-Cell Lymphoma in a Kidney Transplant RecipientEdoardo Melilli, Alberto Mussetti, Gabriela Sanz Linares, et al.
Transplantation and Cellular Therapy|November 14, 2025
EASIX Does Not Add Prognostic Value Beyond Lactate Dehydrogenase and ECOG Performance Status in CAR T-Cell Therapy: A GETH-TC StudyMarta Peña, Diego Fernando Martinez, Lucía López-Corral, et al.
Leukemia & Lymphoma|April 16, 2014
Autoimmune diseases during treatment with immunomodulatory drugs in multiple myeloma: selective occurrence after lenalidomideVittorio Montefusco, Monica Galli, Francesco Spina, et al.
Leukemia & Lymphoma|February 5, 2015
Bendamustine in relapsed/refractory multiple myeloma: the "real-life" side of the moonPellegrino Musto, Vincenzo Ludovico Fraticelli, Giovanna Mansueto, et al.
Leukemia|April 17, 2025
GVHD prophylaxis in matched related stem cell transplantation: Why post-transplant cyclophosphamide can be recommended a study by the EBMT transplant complications working partyOlaf Penack, Mouad Abouqateb, Christophe Peczynski, et al.
Scientific Reports|June 22, 2026
Use of mesenchymal stromal cells derived from the Wharton's jelly of human umbilical cord for treating patients with steroid-resistant graft versus host disease: predicting clinical response by a validated immunopotency assaySilvia Torrents, Ana García-Buendía, Margarita Codinach, et al.
Bone Marrow Transplantation|August 19, 2025
Post-transplantation cyclophosphamide and antithymocyte globulin in 8/10 HLA-mismatched unrelated donor transplantation: the analysis on behalf of the transplant complications working party of the EBMTIvan Moiseev, Mouad Abouqateb, Christophe Peczynski, et al.
Pageof 10

Showing results (41-50 of 100) with videos related to

Sort By:
Pageof 10
JMIR Formative Research|February 18, 2021
Use of Telehealth for Domiciliary Follow-up After Hematopoietic Cell Transplantation During the COVID-19 Pandemic: Prospective Pilot StudyAlberto Mussetti, Maria Queralt Salas, Maria Condom, et al.
Supportive Care in Cancer : Official Journal of the Multinational Association of Supportive Care in Cancer|June 11, 2026
Assessing the impact of nutritional status at allogeneic stem cell transplantation on clinical outcomesAnnalisa Paviglianiti, Marta Bellver Sanchis, Marta Peña, et al.
Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation|April 10, 2017
Allogeneic Stem Cell Transplantation for Relapsed/Refractory B Cell Lymphomas: Results of a Multicenter Phase II Prospective Trial including Rituximab in the Reduced-Intensity Conditioning RegimenAnna Dodero, Francesca Patriarca, Giuseppe Milone, et al.
Kidney Medicine|August 17, 2021
Acute Kidney Injury Following Chimeric Antigen Receptor T-Cell Therapy for B-Cell Lymphoma in a Kidney Transplant RecipientEdoardo Melilli, Alberto Mussetti, Gabriela Sanz Linares, et al.
Transplantation and Cellular Therapy|November 14, 2025
EASIX Does Not Add Prognostic Value Beyond Lactate Dehydrogenase and ECOG Performance Status in CAR T-Cell Therapy: A GETH-TC StudyMarta Peña, Diego Fernando Martinez, Lucía López-Corral, et al.
Leukemia & Lymphoma|April 16, 2014
Autoimmune diseases during treatment with immunomodulatory drugs in multiple myeloma: selective occurrence after lenalidomideVittorio Montefusco, Monica Galli, Francesco Spina, et al.
Leukemia & Lymphoma|February 5, 2015
Bendamustine in relapsed/refractory multiple myeloma: the "real-life" side of the moonPellegrino Musto, Vincenzo Ludovico Fraticelli, Giovanna Mansueto, et al.
Leukemia|April 17, 2025
GVHD prophylaxis in matched related stem cell transplantation: Why post-transplant cyclophosphamide can be recommended a study by the EBMT transplant complications working partyOlaf Penack, Mouad Abouqateb, Christophe Peczynski, et al.
Scientific Reports|June 22, 2026
Use of mesenchymal stromal cells derived from the Wharton's jelly of human umbilical cord for treating patients with steroid-resistant graft versus host disease: predicting clinical response by a validated immunopotency assaySilvia Torrents, Ana García-Buendía, Margarita Codinach, et al.
Bone Marrow Transplantation|August 19, 2025
Post-transplantation cyclophosphamide and antithymocyte globulin in 8/10 HLA-mismatched unrelated donor transplantation: the analysis on behalf of the transplant complications working party of the EBMTIvan Moiseev, Mouad Abouqateb, Christophe Peczynski, et al.
Pageof 10